278 related articles for article (PubMed ID: 16810368)
1. [Price differences between generic and innovator medicines in Brazil].
Vieira FS; Zucchi P
Rev Saude Publica; 2006 Jun; 40(3):444-9. PubMed ID: 16810368
[TBL] [Abstract][Full Text] [Related]
2. Pseudo-Generics in South Africa: A Price Comparison.
Bangalee V; Suleman F
Value Health Reg Issues; 2019 Sep; 19():87-91. PubMed ID: 31357098
[TBL] [Abstract][Full Text] [Related]
3. Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment.
Nunn AS; Fonseca EM; Bastos FI; Gruskin S; Salomon JA
PLoS Med; 2007 Nov; 4(11):e305. PubMed ID: 18001145
[TBL] [Abstract][Full Text] [Related]
4. High prices for generics in Australia - more competition might help.
Bulfone L
Aust Health Rev; 2009 May; 33(2):200-14. PubMed ID: 19563309
[TBL] [Abstract][Full Text] [Related]
5. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
Mansfield SJ
Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
[TBL] [Abstract][Full Text] [Related]
6. Does the market share of generic medicines influence the price level?: a European analysis.
Dylst P; Simoens S
Pharmacoeconomics; 2011 Oct; 29(10):875-82. PubMed ID: 21797288
[TBL] [Abstract][Full Text] [Related]
7. Does generic entry lower the prices paid for pharmaceuticals in Australia? A comparison before and after the introduction of the mandatory price-reduction policy.
Spinks J; Chen G; Donovan L
Aust Health Rev; 2013 Nov; 37(5):675-81. PubMed ID: 24160374
[TBL] [Abstract][Full Text] [Related]
8. The impact of South Korea's new drug-pricing policy on market competition among off-patent drugs.
Kwon HY; Kim H; Godman B; Reich MR
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):1007-14. PubMed ID: 26394767
[TBL] [Abstract][Full Text] [Related]
9. Developing competitive and sustainable Polish generic medicines market.
Simoens S
Croat Med J; 2009 Oct; 50(5):440-8. PubMed ID: 19839067
[TBL] [Abstract][Full Text] [Related]
10. [Availability of generic drugs in the public sector and prices in the private sector in different regions of Brazil].
Miranda ES; Pinto Cdu B; dos Reis AL; Emmerick IC; Campos MR; Luiza VL; Osorio-de-Castro CG
Cad Saude Publica; 2009 Oct; 25(10):2147-58. PubMed ID: 19851615
[TBL] [Abstract][Full Text] [Related]
11. Lowering generic drug prices: less regulation equals more competition.
Anis AH; Guh DP; Woolcott J
Med Care; 2003 Jan; 41(1):135-41. PubMed ID: 12544550
[TBL] [Abstract][Full Text] [Related]
12. Do higher-priced generic medicines enjoy a competitive advantage under reference pricing?
Puig-Junoy J
Appl Health Econ Health Policy; 2012 Nov; 10(6):441-51. PubMed ID: 22900924
[TBL] [Abstract][Full Text] [Related]
13. Association Between Market Competition and Prices of Generic Topical Dermatology Drugs.
Li DG; Joyce C; Mostaghimi A
JAMA Dermatol; 2018 Dec; 154(12):1441-1446. PubMed ID: 30383117
[TBL] [Abstract][Full Text] [Related]
14. The effect of generic competition on the price of brand-name drugs.
Lexchin J
Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
[TBL] [Abstract][Full Text] [Related]
15. Impact of price deregulation policy on the affordability of essential medicines for women's health: a panel data analysis.
Liu J; Wang L; Liu C; Zhang X
Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):625-631. PubMed ID: 28503962
[TBL] [Abstract][Full Text] [Related]
16. Pricing policies for generic medicines in Australia, New Zealand, the Republic of Korea and Singapore: patent expiry and influence on atorvastatin price.
Roughead EE; Kim DS; Ong B; Kemp-Casey A
WHO South East Asia J Public Health; 2018 Sep; 7(2):99-106. PubMed ID: 30136668
[TBL] [Abstract][Full Text] [Related]
17. Analysis of Medicine Prices in New Zealand and 16 European Countries.
Vogler S; Kilpatrick K; Babar ZU
Value Health; 2015 Jun; 18(4):484-92. PubMed ID: 26091603
[TBL] [Abstract][Full Text] [Related]
18. [The effect of generic price competition on drug consumption and health insurance pharmaceutical expenditures in Hungary].
Répásy B; Endrei D; Zemplényi A; Agoston I; Hornyák L; Nagy Z; Csákvári T; Vajda R; Boncz Imre
Acta Pharm Hung; 2015; 85(3):83-8. PubMed ID: 26642646
[TBL] [Abstract][Full Text] [Related]
19. The Evolution of Supply and Demand in Markets for Generic Drugs.
Frank RG; McGuire TG; Nason I
Milbank Q; 2021 Sep; 99(3):828-852. PubMed ID: 34075623
[TBL] [Abstract][Full Text] [Related]
20. Encouraging the use of generic medicines: implications for transition economies.
King DR; Kanavos P
Croat Med J; 2002 Aug; 43(4):462-9. PubMed ID: 12187525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
